Lifelong Genetic Inhibition of PCSK9 and Hepatic Safety
This genetic association study investigates whether the full spectrum of rare PCSK9 loss-of-function variants is associated with incident liver-related outcomes, given the development of therapies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).
Authors
- Vincenza Colonna (ORCID: https://orcid.org/0000-0002-3966-0474)
- Carlo Maiorca (ORCID: https://orcid.org/0000-0002-1142-1041)
- Silvia Buonaiuto (ORCID: https://orcid.org/0000-0002-7423-7110)
- Daniele Tramontano (ORCID: https://orcid.org/0000-0002-6514-2451)
- Allegra Via
- Ilaria Pirona
- Laura D’Erasmo
- Marcello Arca
- Alessia Di Costanzo
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Tennessee Health Science Center (US)
- University of the Sacred Heart (JP)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-09-10
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.32994
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 8.01